Sacituzumab govitecan structure
|
Common Name | Sacituzumab govitecan | ||
---|---|---|---|---|
CAS Number | 1491917-83-9 | Molecular Weight | 1601.77000 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C76H104N12O24S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Sacituzumab govitecanSacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity[1]. |
Name | Sacituzumab govitecan |
---|---|
Synonym | More Synonyms |
Description | Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity[1]. |
---|---|
Related Catalog | |
In Vivo | Sacituzumab govitecan (IMMU-132) (17.5 mg/kg; twice weekly for 4 weeks) results in significant anti-tumor effects in mice bearing human gastric cancer xenografts[1]. |
References |
Molecular Formula | C76H104N12O24S |
---|---|
Molecular Weight | 1601.77000 |
Exact Mass | 1600.70000 |
PSA | 499.15000 |
LogP | 5.09770 |
Storage condition | 2-8°C |
hRS7-SN38 |
IMMU-132 |
IMMU 132 |
N-[4-(-Carboxycyclohexylmethyl)]maleimide |